Skip to main content
SHIFT Newsroom
Read the latest published stories →Medicine news and evidence →

1.74 kg Average Lean Loss: Prevent GLP-1 Muscle Loss in UK Men

Published 25 September 2026 · SHIFT Team

Decorative GLP-1 muscle loss title card

GLP-1 medicines commonly cause some loss of lean tissue during rapid weight loss, but most of the weight lost is fat, and clinically meaningful muscle loss is largely preventable. A 2025 meta-analysis of randomised trials found an average lean-mass drop of 1.74 kg, well below the scale of fat loss most men achieve. The fix is straightforward: eat enough protein, start resistance training early, and get your muscle checked if you're on a higher dose or losing weight fast.

TL;DR:

- Most muscle loss during GLP-1 treatment is modest, averaging around 1.74 kg, and mainly occurs due to decreased calorie and protein intake during rapid weight loss.
- Higher doses, longer treatment periods, older age, and pre-existing low muscle mass increase the risk of more significant muscle loss, especially if weight loss exceeds 5% per month.
- Adequate daily protein intake of 1.2 to 1.6 grams per kilogram of body weight and regular resistance training with compound movements can largely prevent meaningful muscle decline.
- Muscle function assessments, such as grip strength and mobility tests, are crucial for detecting true functional decline that DXA scans may not fully capture.
- Consistent monitoring and adjustments in diet and exercise, along with clinical guidance, are essential to manage and mitigate muscle loss risks during GLP-1 therapy.

Table of Contents

What is GLP-1 muscle loss and why does it happen?

Some loss of lean tissue alongside fat is a near-universal feature of rapid weight loss, whatever causes it, and GLP-1 receptor agonists like semaglutide and tirzepatide are no exception. The clinical term for this is "lean mass loss" or "lean soft-tissue loss", which is broader than muscle alone. It includes muscle, connective tissue, organ tissue and some water, which is why researchers use DXA scans to measure it rather than assuming every kilogram lost is muscle.

A 2025 systematic review and meta-analysis of seven randomised controlled trials involving 821 patients found that GLP-1 receptor agonists prescribed at obesity-management doses produced an average absolute lean-mass decline of 1.74 kg, with a 95% confidence interval running from 0.45 kg to 3.04 kg. That range matters. It tells you the effect is real and consistent across trials, but the size of it varies a fair amount from person to person and study to study.

The same review found something that sounds contradictory at first: lean mass as a proportion of total body weight actually went up in most trials, even as the absolute amount fell. That happens because fat loss usually outpaces muscle loss by a wide margin, so what's left behind is proportionally more muscle, even though you have less of it overall. It's a subtle point, but it's the difference between "you're losing muscle" and "you're losing weight, and some of what goes is muscle."

Not every GLP-1 medicine behaves identically here. The same 2025 meta-analysis noted that semaglutide subgroups showed some of the largest absolute lean-mass reductions among the agents studied.

It reflects a long treatment period and substantial overall weight change.

What is GLP-1 muscle loss and why does it happen? — overview diagram

Measurement itself is a limitation worth understanding. Most trial data comes from DXA (dual-energy X-ray absorptiometry) scans, which measure lean soft tissue rather than skeletal muscle specifically. Some clinics and gyms use bioelectrical impedance analysis (BIA) instead, which is quicker and cheaper but less precise, particularly in people with fluid shifts from rapid weight loss. That inconsistency between measurement tools is one reason different studies report different numbers for what sounds like the same thing.

A handful of other gaps are worth flagging before you take any single statistic as gospel:

Reviews published in high-impact journals frame this the right way: the question isn't simply how many kilograms of lean tissue disappear, but whether that loss is adaptive (proportionate, expected, without functional consequence) or maladaptive (excessive, tied to poor intake, and linked to weakness). A narrative review on lean mass and musculoskeletal preservation argues that muscle quality and physical function deserve at least as much attention as the number on a DXA report.

How GLP-1 medicines can lead to muscle loss

GLP-1 receptor agonists don't attack muscle directly. The pathway from medication to lean tissue loss runs through several interconnected mechanisms, some of which you can influence and some you can't.

Mechanisms contributing to GLP-1 lean loss

Negative energy balance is the primary driver. GLP-1 medicines work partly by suppressing appetite and slowing gastric emptying, which leads most people to eat considerably less. Any large, sustained calorie deficit, whatever causes it, pushes the body to draw energy from both fat stores and lean tissue. The body doesn't perfectly ring-fence muscle during weight loss; it draws on whatever's available; that's why proportionate lean loss during rapid fat loss is expected rather than exceptional.

Reduced intake compounds the problem specifically for protein. It's not just total calories that matter here. When appetite drops, protein intake tends to fall disproportionately because people gravitate toward small, plain, easy-to-tolerate foods rather than protein-dense meals. Without a strong dietary protein signal, the body has less raw material to preserve muscle tissue, and the process that would otherwise protect it against breakdown weakens.

Gastrointestinal side effects make this worse. Nausea, early fullness, reflux and altered bowel habits are among the most commonly reported issues with GLP-1 therapy, and UK regulatory guidance from the MHRA notes these effects are common enough to generate thousands of safety reports. When you feel queasy, eating enough protein at each meal becomes genuinely difficult, which loops back into the intake problem above.

Hormonal and adaptive metabolic responses play a supporting role. Rapid weight loss triggers changes in hormones linked to appetite and energy expenditure, sometimes reducing the anabolic (muscle-building) signal available to your body. This doesn't happen in isolation; it interacts with everything else on this list.

Reduced activity accelerates disuse atrophy. People who feel less hungry, more fatigued, or nauseous often move less without necessarily noticing the drop. Muscle responds to use; taken away, it shrinks faster, independent of diet. This is arguably the most preventable piece of the whole picture, because it's the one most directly within your control day to day.

A final clarification worth holding onto: DXA-derived "lean mass" and "skeletal muscle mass" are related but not identical. Lean mass includes organs, connective tissue and body water alongside muscle, so a DXA report showing lean mass loss doesn't tell you precisely how much of that is muscle specifically. This is one reason function-based assessments matter alongside scan results.

How much muscle loss typically occurs, and who's most at risk

Trial data gives a reasonable sense of scale, but the risk isn't distributed evenly across every patient.

The headline numbers, again, in context: the pooled meta-analysis figure is an average absolute lean-mass decline of around 1.74 kg, with individual trial subgroups (like the semaglutide and tirzepatide data referenced above) showing considerably larger reductions over longer treatment periods. As a proportion of total weight lost, lean tissue typically accounts for a meaningful but minority share, with fat mass making up the larger portion in most well-conducted trials.

Whether that level of loss matters clinically depends heavily on who you are and how you're losing weight. Several factors raise the risk of lean loss becoming a real problem rather than an expected side effect of getting lighter:

Watch for functional signals, not just the scales. A falling number on a DXA scan is one thing, but real-world function tells you more day to day. Reduced grip strength, taking noticeably longer to stand up from a low chair, unusual fatigue during normal activity, or finding stairs harder than they used to be are all practical red flags worth raising with a clinician rather than dismissing as "just getting older" or "just the diet."

Preventing muscle loss: nutrition and protein guidance

Food is the first and most controllable lever you have. Getting this right doesn't require a dramatic diet overhaul, just consistent attention to protein at every meal.

  1. Target 1.2 to 1.6 grams of protein per kilogram of bodyweight daily. This range is supported by the LEAN-PREP trial protocol, which has set a pragmatic target of 1.6 g/kg/day for its participants on semaglutide and tirzepatide, specifically to test whether that level protects muscle during treatment. For a 90 kg man, that's roughly 108 to 144 grams of protein a day, which is more than most British diets deliver by default.
  2. Spread protein evenly rather than loading it into one meal. Aim for at least 25 grams of protein at each meal where possible. Muscle-preserving processes respond better to steady protein delivery through the day than to one large protein-heavy dinner and two protein-light meals either side.
  3. Make breakfast a protein meal, not an afterthought. Eggs, Greek yoghurt, or a protein shake in the morning sets you up better than toast alone, particularly on days when appetite fades fast after that.
  4. Keep protein-rich snacks on hand for low-appetite days. Cottage cheese, boiled eggs, tinned fish, or a small protein shake can deliver a meaningful protein hit without requiring a full meal you don't feel able to face.
  5. Use fortified milks and compact protein portions when nausea limits volume. When GI side effects are at their worst, energy-dense, protein-dense options in small volumes, such as a 25g whey drink or a small pot of high-protein yoghurt, achieve more than trying to force down a full plate.
  6. Know when to escalate to oral nutritional supplements or dietitian referral. If intake has been consistently poor for more than a couple of weeks, or you're losing weight faster than 5% of body weight a month, that's the point to ask your GP or prescriber about a dietitian referral rather than trying to push through alone.
  7. Don't ignore micronutrients and hydration. Vitamin D and iron status are worth checking periodically, particularly if intake has dropped, and hydration needs closer attention when nausea, vomiting or reduced fluid intake are in the picture.

Pro Tip: If plain chicken and rice feels unappealing on a queasy day, cold or room-temperature protein sources, like yoghurt, cottage cheese, or a chilled protein shake, are often easier to tolerate than hot meals when nausea is at its worst.

Preventing muscle loss: a practical resistance-training programme

Protein alone gives your muscles the raw material to rebuild. Resistance training gives them a reason to. Skeletal muscle also plays a direct role in glucose disposal, so preserving it during weight loss isn't only about strength; it supports longer-term metabolic health, particularly relevant if you have or are at risk of type 2 diabetes.

Here's a simple, progressive structure that works for most men starting out, including complete beginners:

  1. Start with two to three resistance sessions a week. More isn't automatically better here, especially while you're also adjusting to a new medicine and possibly reduced energy intake. Consistency across a few sessions beats an ambitious plan you abandon after a fortnight.
  2. Build sessions around compound movements. Squats, presses, rows, and hip hinges (like deadlifts or their easier variants) recruit more muscle per session than isolation exercises, giving you more return for the time invested.
  3. Apply progressive overload gradually. Add small amounts of weight, reps, or sets over time rather than jumping straight to heavy loads. This is where most beginners either progress too fast and get discouraged by soreness, or too slowly and see no change.
  4. Include eccentric emphasis where it's safe to do so. Research on eccentric-focused training shows a slow, controlled lowering phase, roughly 3 to 5 seconds on the way down, drives strong structural adaptation, and it's particularly useful for people starting from lower muscle mass or reduced mobility.
  5. Adapt for home or limited mobility. Resistance bands, bodyweight squats, wall presses, and chair-supported variations all count as legitimate resistance training if a gym isn't accessible or comfortable right now.
  6. Progress safely, and know when to seek supervision. If you have joint pain, balance issues, or haven't exercised in years, a session or two with a physiotherapist or qualified trainer to check your form is worth far more than guessing.
  7. Pair resistance work with aerobic activity and proper recovery. Walking, cycling, or swimming alongside resistance sessions supports cardiovascular health without competing for the same recovery resources, provided you're giving muscles at least a day's rest between sessions targeting the same muscle groups.

Pro Tip: You don't need a gym membership to start. Two sessions a week with resistance bands and bodyweight moves, done consistently for two months, will do more for muscle preservation than an ambitious programme you only manage once.

For more detail on adapting movement safely while on GLP-1 medicines, including pacing and injury prevention, see our guide to exercising on GLP-1 treatment.

Supplements, side effects, and when to speak to your prescriber

Diet and training do most of the heavy lifting, but a few supplements have a reasonable evidence base as adjuncts, and managing GI side effects properly protects the intake you're already working hard to maintain.

Creatine has a plausible mechanistic case for supporting muscle preservation during weight loss, though the evidence specifically in GLP-1 users remains limited rather than conclusive. Leucine and HMB show benefit in certain contexts, particularly older adults with lower baseline muscle mass, but the evidence is phenotype-specific rather than universal. Omega-3 fatty acids are best considered adjunctive support rather than a standalone solution.

None of these replace adequate protein and resistance training; they sit alongside them, and only where relevant to your circumstances.

Managing nausea and reduced intake matters just as much as any supplement choice:

Always check new supplements or medication changes with your prescriber or pharmacist first, particularly given the documented safety-reporting patterns around GLP-1 GI side effects noted by UK regulators. Our guide on managing GLP-1 side effects covers this in more practical detail.

Monitoring muscle: tests, function checks, and when to escalate

You can't manage what you don't measure, but not every measurement method tells you the same thing.

DXA scans give the most accurate picture of lean versus fat mass and are the gold standard used in most research, though access outside specialist or research settings is limited. BIA (bioelectrical impedance analysis) is far more accessible, quick, and inexpensive, but less reliable, particularly when hydration status is fluctuating, which it often does during rapid weight loss. Clinical function tests, grip strength, sit-to-stand timing, and simple walking assessments, don't measure muscle mass directly but tell you how well the muscle you have is actually working, which arguably matters more day to day.

A sensible monitoring cadence looks like this:

A narrative review on musculoskeletal preservation specifically recommends this kind of risk-based, staged monitoring rather than a one-size-fits-all schedule.

SHIFT's perspective: turning the evidence into a workable plan

The research is genuinely reassuring once you get past the headline numbers, but reassurance on its own doesn't build muscle. It's the follow-through that counts, and that's where most men, understandably, lose momentum.

At Shift Some Timber Ltd, The Programme is built around that gap. Grub turns protein targets into meals that fit around a working week rather than a research protocol. Fit takes the resistance-training principles set out above and adapts them to whatever equipment, time, and confidence a man actually has, whether that's a gym or a living room floor. My Timber tracks progress beyond the scales, so a man can see whether strength and function are holding up, not just whether the number on the scale is falling.

None of this replaces clinical oversight. Our model pairs practical, everyday support with clinical assessment, prescribing, and dispensing handled by appropriately regulated partners, because the decisions about dose, monitoring, and when to escalate concerns genuinely need a clinician in the loop. What The Programme adds is the daily discipline, protein at the right meals, sessions that actually happen, honest tracking of what's changing, that turns good evidence into a good outcome.

— Matt O’Brien

Worried about muscle loss on GLP-1 treatment? Here's how SHIFT can help

Reading the evidence is one thing. Putting it into practice on a Tuesday evening after a long shift, with your appetite half gone and no idea where to start with a resistance band, is another matter entirely. Shift Some Timber Ltd exists to close that gap for UK men, connecting clinical oversight of GLP-1 treatment with the practical nutrition and movement support most prevention guides simply describe rather than deliver.

Shift Some Timber Ltd

The Programme brings together clinical assessment and monitoring with Grub for realistic, protein-focused food plans, Fit for resistance training that fits around your actual week, and My Timber for tracking the things that matter beyond the scales, strength, energy, and function. Support runs before, during, and after treatment, including for men who started elsewhere or have already stopped medication and want help maintaining what they've built. Whatever your situation, always speak to your prescriber before changing medication, doses, or starting new supplements.

If you want a clearer sense of how clinical support compares to going it alone through a GP, our comparison of GP versus specialist weight-management services is a useful starting point. To see how The Programme works in practice, visit Shift Some Timber and get a sense of whether structured support is the right next step for you.

Sources

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

Can you regain muscle lost from GLP-1 treatment?

Yes. Muscle responds to resistance training and adequate protein regardless of whether it was lost due to GLP-1 therapy, ageing, or any other cause. Consistent training and hitting your protein targets over several months can rebuild strength and lean tissue, even while you continue treatment.

What does muscle loss from GLP-1 feel like?

Most people don't feel lean-mass loss directly, since it happens gradually alongside fat loss. Practical signs include feeling weaker during everyday tasks, needing more effort to climb stairs, slower recovery after activity, or a noticeable drop in grip strength.

How do I build muscle while on GLP-1 medication?

Combine two to three resistance-training sessions a week using compound movements with a daily protein target of 1.2 to 1.6 grams per kilogram of bodyweight, spread evenly across meals. This approach reflects the target used in the ongoing LEAN-PREP trial testing muscle preservation during semaglutide and tirzepatide therapy.

Why shouldn't I panic about GLP-1 muscle loss?

Most weight lost on GLP-1 medicines is fat, not muscle, and the average absolute lean-mass decline reported in trials is 1.74 kg, a modest figure relative to typical total weight loss. Clinically significant muscle loss is largely preventable with adequate protein, regular resistance training, and periodic monitoring, so it's a manageable risk rather than an inevitable outcome.

Does stopping GLP-1 treatment affect muscle mass?

Stopping treatment often brings appetite and food intake back up, which can support muscle recovery if protein intake and training continue. Our guide on what happens after stopping GLP-1 treatment covers weight and appetite changes in more detail.